TPO peptide compounds for treatment of anemia

Details TPO peptide compounds for treatment of anemia TPO peptide compounds for treatment of anemia

2006-02-14

2009-11-10

Tsang, Cecilia (Department: 1654)

Drug, bio-affecting and body treating compositions

Designated organic active ingredient containing

Peptide containing doai

C514S002600, C514S013800, C514S014800, C514S015800, C514S017400, C530S300000, C530S324000, C530S325000, C530S326000, C530S327000

Reexamination Certificate

active

07615533

ABSTRACT:
Peptide compounds that bind to and activate the thrombopoietin receptor (c-mpl or TPO-R) or otherwise act as a TPO agonist are disclosed.

REFERENCES:
patent: 6251864 (2001-06-01), Dower et al.
patent: 2002/0165178 (2002-11-01), Schetter et al.
patent: 2002/0187124 (2002-12-01), Takahashi
patent: 2004/0028649 (2004-02-01), Gianni
patent: 2005/0282277 (2005-12-01), MacDonald et al.
patent: 2006/0040866 (2006-02-01), MacDonald et al.
patent: 2008/0119384 (2008-05-01), Yurkow et al.
patent: WO 95/21626 (1995-08-01), None
patent: WO 2004/026332 (2004-04-01), None
patent: WO 2005/023834 (2005-03-01), None
Merck manual, Etiology of Anemia, pp. 1-2. Accessed Jun. 10, 2008.
Merck manual, Evaluation of Anemia, pp. 1-4. Accessed Jun. 10, 2008.
Merck manual, Introduction to Anemia, p. 1. Accessed Jun. 10, 2008.
Merck manual, Anemia of Chronic Disease, pp. 1-2. Accessed Jun. 10, 2008.
Merck manual, Treatment of Anemia, p. 1. Accessed Jun. 10, 2008.
Merck manual, Aplastic Anemia, pp. 1-3, Accessed Jun. 10, 2008.
Merck manual, Hypoproliferative Anermia, pp. 1-2. Accessed Jun. 10, 2008.
Merck manual, Iron Deficiency Anemia, pp. 1-5. Accessed Jun. 10, 2008.
Merck manual, Megaloblastic Macrocytic Anemias, pp. 1-3. Accessed Jun. 10, 2008.
Merck manual, Myelophthisic Anemia, pp. 1-2. Accessed Jun. 10, 2008.
De Serres, M, Ellis B, Dillberger JE, Rudolph SK, Hutchins JT, Boytos CM, Weigl DL, DePrince RB, Immunogenicity of Throbopoietin Mimetic Peptide GW395058 in BALB/c Mice and New Zealand White Rabbits: Evaluation of the Potential for Throbopoietin Neutralizing Antibody Production in Man, Stem Cells, 1999, 17: 203-209.
Zdenko P and Slaninova J, The 1- and 2-Naphthylalanine Analogs of Oxytocin and Vasopressin, Coolect. Czech. Chem. Commun., 1995, 60: 2170-2177.
Case B.C. et al: “The pharmacokinetics and pharmacodynamics of GW39505, a peptide agonist of the thrombopoietin receptor, in the dog, a large-animal model of chemotherapy-induced thrombocytopenia” Stem Cells, Alphamed Press, Dayton, Oh, vol. 18, No. 5, 2000, pp. 360-365, XP002421199, ISSN: 1066-5099.
De Serres M. et al: “Pharmacokinetics and hematological effects of the PEGylated thrombopoietin peptide mimetic GW395058 in rats and monkeys after intravenous or subcutaneous administration” Stem Cells, Alphamed Press, Dayton, OH, US, vol. 17, No. 6, 1999, pp. 316-326, XP002421200 ISSN: 1066-5099.
Singer S.C. et al.: “Pegylated thrombopoietin (TPO)-Mimetic peptides bind human to TPO receptor causing proliferation and maturation of megakaryocytes in vitro” Blood, W.B. Saunders Company, Orlando, FL, US, vol. 92, No. 10 Suppl PT1-2, Nov. 15, 1998, p. 568A, XP009079489.
International Search Report dated Apr. 26, 2007 for corresponding Appln. No. PCT/US2006/005322.

Affiliated with

Also associated with

Rating

TPO peptide compounds for treatment of anemia does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with TPO peptide compounds for treatment of anemia, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and TPO peptide compounds for treatment of anemia will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-4143307